Erectile dysfunction : causes, risk factors, and management /

Detalles Bibliográficos
Clasificación:Libro Electrónico
Otros Autores: Grant, Paul Steven (Editor )
Formato: Electrónico eBook
Idioma:Inglés
Publicado: New York : Nova Biomedical, Nova Science Publishers, Inc., [2012]
Colección:Human sexuality.
Sexology research and issues.
Temas:
Impotence.
Erectile Dysfunction
Impuissance sexuelle.
HEALTH & FITNESS > Diseases > General.
MEDICAL > Clinical Medicine.
MEDICAL > Diseases.
MEDICAL > Evidence-Based Medicine.
MEDICAL > Internal Medicine.
Acceso en línea:Texto completo
Tabla de Contenidos:
  • ERECTILE DYSFUNCTION
  • ERECTILE DYSFUNCTION
  • Contents
  • Foreword
  • Part One
  • Introduction
  • References
  • A Primary Care Approach to Erectile Dysfunction
  • Abstract
  • Introduction
  • Assessment of ED
  • Common Causes of Erectile Dysfunction
  • Baseline Investigations
  • Men in the Following Categories Require Referral
  • Developing a Treatment Plan
  • Phase 1: Stabilise General Clinical Condition
  • Phase 2: Treat Correctable Causes
  • Phase 3: Initiate Specific Therapy for Erectile Dysfunction
  • Phase 4: Onward Referral
  • Conclusion References
  • Erectile Dysfunction: Causes, Risk Factors and Management
  • Abstract
  • Introduction
  • Epidemiology
  • Physiology of Erection
  • Pathophysiology of Erectile Dysfunction
  • Psychogenic ED
  • Neurogenic ED
  • Hormonal Causes of ED
  • Vascular Causes of ED
  • Drug-Induced Erectile Dysfunction
  • Erectile Dysfunction due to other Systemic Diseases and Ageing
  • Renal Disease
  • Spinal Cord Injury
  • Correlations of ED with CAD and DM
  • Correlation of ED with Lower Urinary Tract Symptoms (LUTS)
  • Clinical Evaluation Quantification of the Severity of Erectile Dysfunction and Improvement
  • Physical Examination
  • Laboratory Studies
  • Special Studies
  • Penile Duplex Doppler Imaging
  • Management of Erectile Dysfunction
  • I. Medical and other Non-surgical Treatment
  • Phosphodiesterase Type 5 Inhibitors (PDE5 Inhibitors)
  • 1. Sildenafil Citrate (Viagra)
  • 2. Vardenafil (Levitra)
  • 3. Tadalafil (Cialis)
  • 4. Use of PDE5 Inhibitors and Cardiovascular Safety
  • Apomorphine (Uprima)
  • Adrenergic-Receptor Antagonists
  • 1. Phentolamine (Regitine) 2. Yohimbine
  • Trazodone (Desyrel, Mesyrel)
  • Dietary Supplements and Erectile Dysfunction
  • 1. Ginkgo Bilboa
  • 2. L-Arginine
  • Intracavernosal and Intraurethral Therapy
  • 1. Alprostadil (Prostaglandin E1, Caverject, Medicated Urethral System for Erection)
  • 2. Papaverine
  • 3. Phentolamine (Regitine)
  • 4. Moxisylyte Chlorohydrate
  • 5. Chlorpromazine (Thorazine)
  • 6. Vasoactive Intestinal Polypeptide (VIP)
  • Testosterone
  • Vacuum Constrictive Device
  • II. Surgical Treatment
  • Penile Prostheses Implantation Penile Revascularization
  • Venectomy
  • III. Future Treatments
  • Gene Therapy
  • 1. Gene Therapy and NOS
  • 2. Gene Therapy and the Human Calcium-Sensitive Potassium Channel Subtype
  • 3. Gene Therapy and Vascular Endothelial Growth Factor (VEGF) and other Molecular Targets
  • Conclusion
  • References
  • Current and Emerging Novel Diagnostic Tools for the Diagnosis of Male Erectile Dysfunction
  • Abstract
  • Introduction
  • Consensus and Major International Guidelines on the Investigations of ED

Ejemplares similares